跳至主要内容
临床试验/NCT03466528
NCT03466528已完成2 期

A Prospective Randomised Controlled Trial of the Effect of Magnesium Sulphate Administration on Red Cell Transketolase Activity in Alcohol Dependent Patients at Risk of Wernicke Korsakoff Syndrome Treated With Thiamine

Glasgow Royal Infirmary1 个研究点 分布在 1 个国家目标入组 127 人开始时间: 2016年12月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
127
试验地点
1
主要终点
Change in Erythrocyte transketolase activity

研究概览

简要总结

Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency causing Wernicke's Encephalopathy (WE).

Intravenous (IV) thiamine replacement is standard practice in the treatment of alcoholic patients presenting to the Accident & Emergency (A&E) department, however routine co-supplementation with magnesium (administered IV as magnesium sulphate ), which is required as a co-factor for thiamine in some metabolic processes, e. g. on the activity of the enzyme transketolase in red blood cells, is not routine practice in the treatment of these patients. Without correction of concomitant magnesium deficiency there may be impaired utilisation of thiamine resulting in a failure to treat WE.

This study is designed to determine if administration of magnesium to AUD patients affects red cell transketolasae and serum lactate concentrations by itself, or only acts to increase the effect of thiamine on the activity of this enzyme.

详细描述

This is a 3- arm randomised, open label, controlled study in a cohort of alcoholic patients admitted through A&E. Patients will be randomised to concurrent infusion of one of the following:

  • Arm 1: IV thiamine
  • Arm 2: IV magnesium sulphate followed by delayed IV thiamine
  • Arm 3: IV thiamine and IV magnesium sulphate Thiamine will be administered as IV Pabrinex, a compound preparation which also contains B vitamins and vitamin C. Administration of IV Pabrinex is standard care in this patient group and magnesium sulphate is routinely co-administered at Glasgow Royal Infirmary.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent
  • Male or non-pregnant or breastfeeding females ≥18 years of age For women of child-bearing potential a negative pregnancy test will be required prior to treatment.
  • (Women of non-childbearing potential are defined as those defined as women who are post-menopausal or permanently sterilised (e.g. hysterectomy, tubal occlusion, bilateral salpingectomy).
  • Chronic alcohol dependence as confirmed by
  • FAST questionnaire
  • GMAWS scale

排除标准

  • Unable to give consent
  • Less than 18 years of age
  • Chronic renal or hepatic failure/hepatic encephalopathy (investigator assessment as documented in past medical history i.e. Clinical Portal.)
  • Known hypersensitivity or previous allergy to any of the active substances in either trial medication, or to excipients
  • Severe concurrent medical condition that would prevent participation in study procedures (e.g. myasthenia gravis, clinically significant cardiac disease, or cardiac failure with severe pulmonary oedema)

研究组 & 干预措施

Standard treatment - Pabrinex alone

Active Comparator

Pabrinex alone

干预措施: Pabrinex (Drug)

Pabrinex + magnesium sulphate

Active Comparator

standard treatment and magnesium sulphate

干预措施: Magnesium Sulfate (Drug)

Pabrinex + magnesium sulphate

Active Comparator

standard treatment and magnesium sulphate

干预措施: Pabrinex (Drug)

Magnesium sulphate alone

Experimental

This group receives the study intervention and delayed Pabrinex

干预措施: Magnesium Sulfate (Drug)

结局指标

主要结局

Change in Erythrocyte transketolase activity

时间窗: 0 and 2 hours

this is a biochemical marker of thiamine activity measured in units per gram of haemoglobin

Change in serum lactate

时间窗: 0 and 2 hours

Biochemical marker of metabolic dysfunction (expressed as mmol/L)

Change in rate of resolution of alcohol withdrawal syndrome

时间窗: days

time

次要结局

  • lactate dehydrogenase(0 and 2 hours)
  • pre and post magnesium(0 and 2 hours)
  • pre and post red cell thiamine(0 and 2 hours)
  • establish baseline micronutrient status of patients with alcohol withdrawal syndrome(o and 2 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Donogh Maguire

Emergency Medicine Consultant

Glasgow Royal Infirmary

研究点 (1)

Loading locations...

相似试验